Inactive Instrument

GreenLight Biosciences Holdings

Equities

GRNA

US39536G1058

Biotechnology & Medical Research

GreenLight Biosciences : August investor presentation

August 15, 2022 at 02:04 pm

GreenLight highlights its vision and key developments. Download the full PDF below.

GreenLight-investor-presentation-August-2022Download

Attachments

Original Link
Original Document
Permalink

Disclaimer

Greenlight Biosciences Holdings PBC published this content on 15 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2022 13:02:48 UTC.

Latest news about GreenLight Biosciences Holdings

Greenlight Biosciences Holdings Announces Resignation of Directors	24/07/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Composite Index	24/07/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from S&P TMI Index	24/07/23	CI
A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings from stockholders.	23/07/23	CI
GreenLight Biosciences Holdings announced that it has received $67.075 million in funding from a group of investors	23/07/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Biotechnology Index	19/07/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell Small Cap Comp Growth Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 2000 Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 3000 Growth Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell Small Cap Completeness Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 2500 Growth Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 2000 Dynamic Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 3000E Growth Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 2000 Growth Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 2500 Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 3000 Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from Russell 3000E Index	23/06/23	CI
GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from S&P Global BMI Index	19/06/23	CI
GreenLight Biosciences Holdings announced that it expects to receive $115 million in funding from a group of investors	28/05/23	CI
GreenLight Biosciences Holdings Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
An affiliate of Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC agreed to acquire GreenLight Biosciences Holdings from stockholders for $42.1 million.	29/03/23	CI
GreenLight Biosciences Holdings Auditor Raises 'Going Concern' Doubt	27/03/23	CI
Rwanda FDA approves Platform Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccine	02/02/23	CI
Greenlight Biosciences Holdings Receives Approval to Initiate Phase I/II Clinical Trial of Covid-19 Mrna Vaccine Candidate	01/02/23	CI
Greenlight Biosciences and Epivax Therapeutics Signs Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines	09/01/23	CI

Chart GreenLight Biosciences Holdings

Duration

Period

More charts

Company Profile

GreenLight Biosciences Holdings, PBC is a pre-commercial stage biotechnology company. The Company has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The Company's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. It has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The Company's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+51.38%	63.85B
IQVIA HOLDINGS INC.	-2.32%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.49%	18.69B
BIO-TECHNE CORPORATION	+2.77%	12.73B
UNITED THERAPEUTICS CORPORATION	+21.44%	12.11B
MEDPACE HOLDINGS, INC.	+27.84%	12.07B

Other Biotechnology & Medical Research